Rutgers Researchers Develop New MRSA Prodrug: Can the Pathogen Gain Resistance?
Daniel Pilch, PhD, discusses the potential of Staphylococcus aureus to develop resistance to TXA709.
Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, breaks down the process of how Staphylococcus aureus (S. aureus) is able to gain resistance to methicillin. Dr. Pilch also explains if the pathogen can gain resistance to a new prodrug he helped develop: TXA709.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Recent Videos
Considering the Impact of Crop Spraying and Antifungal Resistance
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
Deciphering Similarities and Differences in Antifungal and Antibiotic Development
Fidaxomicin Tied to Lower C difficile Recurrence in Immunocompromised Patients
'Tis the Season: Addressing Tick-Borne Illnesses
Impact of Obesity on Antibiotic Treatment Outcomes
Fidaxomicin Reduces Recurrence Risk in High-Risk C difficile Infections
Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae
Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases
No Significant Difference Between Doxycycline and Minocycline for Bone and Joint Infections
Related Content
